Literature DB >> 29158284

Comparative In Vitro Activities of Relebactam, Imipenem, the Combination of the Two, and Six Comparator Antimicrobial Agents against 432 Strains of Anaerobic Organisms, Including Imipenem-Resistant Strains.

Ellie J C Goldstein1,2, Diane M Citron3, Kerin L Tyrrell3, Eliza Leoncio3, C Vreni Merriam3.   

Abstract

Relebactam is an important beta-lactamase inhibitor for certain aerobic organisms, but alone it has no antianaerobic activity, with most anaerobes having MICs of ≥32 μg/ml with the exception of a very few strains. There was no enhancement or antagonism of imipenem activity with the addition of relebactam, including activity against imipenem-resistant strains. The relebactam-imipenem combination had excellent overall activity against the anaerobes tested.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Bacteroides fragilis; Bacteroides thetaiotaomicron; Bilophila wadsworthia; Desulfovibrio spp.; Eggerthella lenta; F. necrophorum; Parabacteroides goldsteinii; anaerobes; imipenem resistance; relebactam

Mesh:

Substances:

Year:  2018        PMID: 29158284      PMCID: PMC5786751          DOI: 10.1128/AAC.01992-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  In Vitro Evaluation of the Activity of Imipenem-Relebactam against 451 Recent Clinical Isolates of Bacteroides Group and Related Species.

Authors:  David R Snydman; Nilda V Jacobus; Laura A McDermott
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

2.  In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program).

Authors:  Sibylle H Lob; Meredith A Hackel; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; James A Karlowsky; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

3.  In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria.

Authors:  Elizabeth B Hirsch; Kimberly R Ledesma; Kai-Tai Chang; Michael S Schwartz; Mary R Motyl; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

  3 in total
  8 in total

Review 1.  Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.

Authors:  George G Zhanel; Courtney K Lawrence; Heather Adam; Frank Schweizer; Sheryl Zelenitsky; Michael Zhanel; Philippe R S Lagacé-Wiens; Andrew Walkty; Andrew Denisuik; Alyssa Golden; Alfred S Gin; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2018-01       Impact factor: 9.546

Review 2.  Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition.

Authors:  Romney Humphries; April M Bobenchik; Janet A Hindler; Audrey N Schuetz
Journal:  J Clin Microbiol       Date:  2021-09-22       Impact factor: 5.948

Review 3.  The Ins and Outs of Susceptibility Testing for New β-Lactam/β-Lactamase Inhibitor Combinations for Gram-Negative Organisms.

Authors:  Tanis C Dingle; Johann Pitout
Journal:  J Clin Microbiol       Date:  2022-04-07       Impact factor: 11.677

Review 4.  β-lactam/β-lactamase inhibitor combinations: an update.

Authors:  Kamaleddin H M E Tehrani; Nathaniel I Martin
Journal:  Medchemcomm       Date:  2018-08-17       Impact factor: 3.597

Review 5.  New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.

Authors:  Juan C Vázquez-Ucha; Jorge Arca-Suárez; Germán Bou; Alejandro Beceiro
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

Review 6.  A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date.

Authors:  Toni A Campanella; Jason C Gallagher
Journal:  Infect Drug Resist       Date:  2020-11-25       Impact factor: 4.003

7.  Cefmetazole Resistance Mechanism for Escherichia Coli Including ESBL-Producing Strains.

Authors:  Ryota Ito; Masato Kawamura; Takumi Sato; Shigeru Fujimura
Journal:  Infect Drug Resist       Date:  2022-10-10       Impact factor: 4.177

Review 8.  Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.

Authors:  Corneliu Ovidiu Vrancianu; Irina Gheorghe; Elena-Georgiana Dobre; Ilda Czobor Barbu; Roxana Elena Cristian; Marcela Popa; Sang Hee Lee; Carmen Limban; Ilinca Margareta Vlad; Mariana Carmen Chifiriuc
Journal:  Int J Mol Sci       Date:  2020-11-12       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.